News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aratana Therapeutics (PETX) To Present At 2014 ACVIM Forum


5/2/2014 9:09:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KANSAS CITY, Kan., May 2, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its presentation plans for the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum, to be held June 4-7, 2014 in Nashville, TN. During the conference, findings from Aratana's ongoing clinical programs will be the subject of three oral presentations and three posters. The company also will host an exhibit booth where interested veterinarians may inquire about Aratana's product candidates.

The ACVIM Forum attracts more than 3,300 veterinary specialists in the field of internal medicine, general practitioners, and veterinary technicians from around the world, and focuses significantly on exploring the latest cutting-edge developments in pet therapeutics.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "We are excited that our scientists and advisors are scheduled to present information regarding several of our development programs at such an important meeting. We intend to become more visible within the specialist veterinary community as a leader in developing innovative pet therapeutics."

Oral Presentations:

Thursday, June 5, 2014: As part of the Forum's Scientific Sessions, Nicola Mason, B.Vet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present her clinical work with Aratana's cancer immunotherapy candidate in an oral presentation titled, "Clinical Evaluation of a Her2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma." (AT-014). 50 minutes.

Friday, June 6, 2014: Aratana's key opinion leaders will deliver a two-part presentation during the Breakfast Pain Symposium, titled, "New Beginnings for Science in Pain Management Exclusively of Veterinary Medicine":

Butch Kukanich, DVM, PhD, DACVCP, Associate Professor, Analytical Pharmacology, Kansas State University College of Veterinary Medicine, will discuss Aratana's EP4 receptor antagonist, grapiprant, for the treatment of osteoarthritis pain in dogs and cats (AT-001). 30 minutes.

Duncan Lascelles, BSc, BVSc, PhD, CertVA, DSAS(ST), DECVS, DACVS, Professor of Small Animal Surgery, North Carolina State University College of Veterinary Medicine, will discuss Aratana's bupivacaine liposome injectable suspension for managing post-operative pain in cats and dogs following surgery (AT-003). 30 minutes.

Poster Presentations:

Aratana will have three posters on display June 5-6, 2014. Abstracts of the posters have been published in the May-June issue of The Journal of Veterinary Internal Medicine (JVIM) and will be available to conference attendees prior to the Forum:

Session: Small Animal Endocrinology
Subject: AT-002 (effectiveness)
Title: Capromorelin, an Orally Active Ghrelin Agonist, Stimulates Appetite and Weight Gain in Inappetant Dogs in a Multi-Site Field Study
Authors: Bill Zollers, Linda Rhodes
Poster: EN-23

Session: Small Animal Endocrinology
Subject: AT-002 (effectiveness)
Title: Capromorelin, an Orally Active Ghrelin Agonist, Stimulates Appetite Growth Hormone, Sustained Increase in IGF-1, Increased Food Intake and Weight Gain in Beagle Dogs
Authors: Bill Zollers, Linda Rhodes
Poster: EN-31

Session: Small Animal Other
Subject: AT-001 (Safety)
Title: Safety of the EP4 Receptor Antagonist, Grapiprant, Administered Daily to Beagle Dogs for 9-Months at 1, 6 and 50 mg/kg
Authors: Lesley Rausch-Derra, Linda Rhodes
Poster: OT-16

Aratana also will host booth #334 in the ACVIM Forum Exhibit Hall June 5-7, 2014. The booth will be attended by Aratana employees, who can provide additional information about the company and its pet therapeutics. Copies of Aratana's scientific posters, company brochure and other key resources will be available.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Aratana's expectations regarding the approval of products; expectations regarding development programs, trials, studies, approvals and commercialization; and expectations regarding Aratana's plans and opportunities.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: Aratana's limited operating history and expectations of losses for the foreseeable future; Aratana's lack of commercial sales; Aratana's failure to obtain any necessary additional financing; Aratana's substantial dependence on the success of certain of Aratana's lead product candidates, AT-001, AT-002, AT-003, AT-004, AT-005, AT-006, AT-007 and AT-008; Aratana's inability to identify, license, develop and commercialize additional product candidates; Aratana's inability to obtain regulatory approval for Aratana's existing or future product candidates; the lack of commercial success of Aratana's current or future product candidates; uncertainties regarding the outcomes of studies regarding Aratana's products; Aratana's inability to realize all of the anticipated benefits of Aratana's acquisitions of Vet Therapeutics and Okapi Sciences; effects of competition; Aratana's failure to attract and keep senior management and key scientific personnel; Aratana's complete reliance on third-party manufacturers and third parties to conduct all Aratana's target animal studies and certain other development efforts; Aratana's lack of a sales organization; Aratana's significant costs of operating as a public company; Aratana's lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of Aratana's customers; impacts of generic products; unanticipated safety or efficacy concerns; Aratana's limited patents and patent rights; Aratana's failure to comply with Aratana's intellectual property license obligations; Aratana's infringement of third party patents and challenges to Aratana's patents or rights; Aratana's failure to comply with regulatory requirements; Aratana's failure to report adverse medical events related to Aratana's products; legislative or regulatory changes; the volatility of Aratana's stock price; Aratana's status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of Aratana's common stock in future financings; the significant control over Aratana's business by Aratana's principal stockholders and management; the potential that a significant portion of Aratana's total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in Aratana's charter documents and under Delaware law; and Aratana's intention not to pay dividends. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 26, 2014, along with Aratana's other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause Aratana's views to change. These forward-looking statements should not be relied upon as representing Aratana's views as of any date subsequent to the date of this press release.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.
jdrumm@tiberend.com; (212) 375-2664

Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES